Keppra I.V. Formulation Is “Approvable” In U.S., Gains Positive EMEA Opinion
This article was originally published in The Pink Sheet Daily
Executive Summary
Revised labeling for antiepileptic, manufacturing information requested by FDA already submitted, firm says.
You may also be interested in...
FDA OKs Intravenous Form Of UCB’s Keppra
UCB will launch the antiepileptic “soon,” though no specific date has been announced.
FDA OKs Intravenous Form Of UCB’s Keppra
UCB will launch the antiepileptic “soon,” though no specific date has been announced.
Keppra Pediatric Epilepsy Claim Clears FDA Under Priority Review
Indication provides for add-on treatment of children ages four years and up with partial onset epileptic seizures. Firm expects sales force expansion to be completed by year-end.